ARDX vs. MIRM, OPK, ETNB, FLXN, XBIT, IONS, OGN, BBIO, CYTK, and APLS
Should you be buying Ardelyx stock or one of its competitors? The main competitors of Ardelyx include Mirum Pharmaceuticals (MIRM), OPKO Health (OPK), 89bio (ETNB), Flexion Therapeutics (FLXN), XBiotech (XBIT), Ionis Pharmaceuticals (IONS), Organon & Co. (OGN), BridgeBio Pharma (BBIO), Cytokinetics (CYTK), and Apellis Pharmaceuticals (APLS). These companies are all part of the "medical" sector.
Mirum Pharmaceuticals (NASDAQ:MIRM) and Ardelyx (NASDAQ:ARDX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.
In the previous week, Ardelyx had 3 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 13 mentions for Ardelyx and 10 mentions for Mirum Pharmaceuticals. Ardelyx's average media sentiment score of 0.95 beat Mirum Pharmaceuticals' score of 0.62 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.
Ardelyx has a net margin of -41.36% compared to Ardelyx's net margin of -69.67%. Mirum Pharmaceuticals' return on equity of -41.65% beat Ardelyx's return on equity.
Mirum Pharmaceuticals presently has a consensus price target of $49.73, indicating a potential upside of 105.40%. Ardelyx has a consensus price target of $12.81, indicating a potential upside of 93.84%. Given Ardelyx's higher probable upside, analysts clearly believe Mirum Pharmaceuticals is more favorable than Ardelyx.
58.9% of Ardelyx shares are owned by institutional investors. 22.9% of Mirum Pharmaceuticals shares are owned by insiders. Comparatively, 5.5% of Ardelyx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Ardelyx has lower revenue, but higher earnings than Mirum Pharmaceuticals. Ardelyx is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Mirum Pharmaceuticals has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Comparatively, Ardelyx has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.
Ardelyx received 411 more outperform votes than Mirum Pharmaceuticals when rated by MarketBeat users. However, 72.37% of users gave Mirum Pharmaceuticals an outperform vote while only 67.57% of users gave Ardelyx an outperform vote.
Summary
Mirum Pharmaceuticals and Ardelyx tied by winning 9 of the 18 factors compared between the two stocks.
Get Ardelyx News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
